Ketanserin reduces graft arteriosclerosis after allogeneic aorta transplantation in rats

Journal of Cardiovascular Pharmacology

Volumn 27, Issue 3, 1996, Pages 307-311

  Geerling, Rob A ^a,b   De Bruin, Ron W F ^a   Scheringa, Marcel ^a   Bonthuis, Fred ^a   Ijzermans, Jan N M ^a   Marquet, Richard L ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Aorta; Arteriosclerosis; Ketanserin; Platelet; Serotonin; Transplantation

Indexed keywords

COLLAGEN; KETANSERIN TARTRATE; SEROTONIN 2 ANTAGONIST; SEROTONIN 2 RECEPTOR; SEROTONIN ANTAGONIST;

ALLOGRAFT; ANIMAL MODEL; ANIMAL TISSUE; AORTA GRAFT; ARTERIOSCLEROSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; GRAFT SURVIVAL; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE AGGREGATION;

ANIMALS; AORTA; ARTERIOSCLEROSIS; BLOOD PRESSURE; KETANSERIN; MALE; PLATELET AGGREGATION; RATS; RATS, INBRED BN; SEROTONIN ANTAGONISTS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030053675     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199603000-00001     Document Type: Article

References (28)

1. O'Neill BJ, Pflugfelder PW, Singh NR, Menkis AH, McKenzie FN, Kostuk WJ. Frequency of angiographic detection and quantitative assessment of coronary arterial disease one and three years after cardiac transplantation. Am J Cardiol 1989;63:1221-6.
2. Gao SZ, Schroeder JS, Alderman EL, et al. Prevalence of accelerated coronary artery disease in heart transplant survivors. Circulation 1989;80(suppl III):100-5.
3. Olivari MT, Homans DC, Wilson RF, Kubo SH, Ring WS. Coronary artery disease in cardiac transplant patients receiving triple drug therapy. Circulation 1989;80(suppl III):111-5.
4. Uretsky BF, Murali S, Reddy PS, et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporin and prednisone. Circulation 1987;76:827-34.
5. McCarthy PM, Starnes VA, Shumway NE. Heart and heartlung transplantation: the Stanford experience. In: Terasaki PI, ed. Clinical transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1989:63-71.
6. Lange SR, English TA, Wallwork J. Heart and heart-lung transplantation at Papworth Hospital, 1979-1989. In: Terasaki PI, ed. Clinical transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1989:73-8.
7. Gao SZ, Schroeder JS, Hunt S, Stinson EB. Retransplantation for severe accelerated coronary artery disease in heart transplant recipients. Am J Cardiol 1988;62:876-81.
8. Foegh ML. Chronic rejection-graft arteriosclerosis. Transplant Proc 1990;22:119-22.
9. Cramer DV, Chapman FA, Wu GD, Harnaha JB, Qian S, Makowka L. Cardiac transplantation in the rat: II. Alteration of the severity of donor graft arteriosclerosis by modulation of the host immune response. Transplantation 1990;4:554-8.
10. Teraoke S, Takahashi K, Toma H, et al. Application of prostacyclin analoque and thromboxane synthetase inhibitor to chronic vascular rejection after kidney transplantation. Transplant Proc 1987;19:3664-8.
11. Teraoke S, Takahashi K, Toma H, et al. New approach to management of chronic vascular rejection with prostacyclin analogue after kidney transplantation. Transplant Proc 1987;19:2115-9.
12. De Clerck F, de Chaffoy de Courcelles D. Amplification mechanisms in platelet activation. In: Meyer P, Marche P, eds. Blood cells and arteries in hypertension and atherosclerosis. New York: Raven Press, 1989;105-40.
13. Vanhoutte PM. Platelet-derived serotonin, the endothelium, and cardiovascular disease. J Cardiovasc Pharmacol 1991;17(suppl 5):S6-12.
14. Nemecek GM, Coughlin SR, Handley DA, Moskowitz MA. Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc Natl Acad Sci USA 1986;83:674-8.
15. Vanhoutte PM, Lüscher TF. Serotonin and the blood vessel wall. J Hypertens 1986;4(suppl 1):S29-35.
16. Arnout J, van Russelt M, Deckmyn H, Vermylen J. Continuous inhibition of serotonin-induced platelet aggregation during chronic ketanserin administration to man can be detected after plasma pH control. Haemostasis 1987;17:344-8.
17. Uehara Y, Nagata T, Matsuoka H, et al. Antiproliferative effects of the serotonin type 2 receptor antagonist, ketanserin, on smooth muscle cell growth in rats. J Cardiovasc Pharmacol 1991;(suppl 2):S154-6.
18. Egan B, Conlon ME, Campbell R, Schork N, Zwiefler A, Julius S. Effects of ketanserin on blood pressure and platelet aggregation in elderly men with mild hypertension. Am J Hypertens 1988;1:324S-30S.
19. De Clerk F. Effects of serotonin on platelets and blood vessels. J Cardiovasc Pharmacol 1991;17:S1-5.
20. Geerling RA, De Bruin RWF, Scheringa M, et al. Suppression of acute rejection prevents graft arteriosclerosis after allogeneic aorta transplantation in the rat. Transplantation 1994;58:1258-63.
21. Fozard JR. Mechanism of the hypotensive effect of ketanserin. J Cardiovasc Pharmacol 1982;4:829-38.
22. Davy M, Midol-Monnet M, Heimburger M, Beslot F, Cohen Y. Peripheral and central cardiovascular effects of ketanserin in conscious normotensive rats. Arch Int Pharmacodyn 1987;290:193-206.
23. Willerson JT, Yao SK, McNatt J, et al. Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury. Proc Natl Acad Sci 1991;88:10624-8.
24. Ashton JH, Benedict CR, Fitzgerald C, et al. Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation 1986;73:572-8.
25. Buckzko W, Gambino MC, De Gaetano G. Prolongation of rat tail bleeding time by ketanserin: mechanism of action. Eur J Pharmacol 1984;103:261-8.
26. Wenting GJ, Woittiez AJJ, Man in't Veld AJ, Schalekamp MADH. 5-HT, alpha-adrenoceptors, and blood pressure: effects of ketanserin in essential hypertension and autonomic insufficiency. Hypertension 1984;6:100-9.
27. De Crée J, Hoing M, De Ryck M, Symoens J. The acute anti-hypertensive effect of ketanserin increases with age. J Cardiovasc Pharmacol 1985;7(suppl 7):S126-7.
28. Serruys PW, Klein W, Tijssen JPG, et al. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty; a multicenter randomized double-blind placebo-controlled trial. Circulation 1993;88:1588-601.